Immunovant Inc SEC Filings

Immunovant, Inc. reported that Michael Geffner, M.D., M.B.A., ceased serving as its Chief Medical Officer effective November 21, 2025, as part of a restructuring of the company’s R&D leadership under Chief Executive Officer Eric Venker, M.D., PharmD. The company and Dr. Geffner entered into a Separation Agreement and General Release that provides severance benefits consistent with his existing employment agreement and includes a standard release of claims in favor of the company.

To support continuity, Dr. Geffner will provide consulting services through April 30, 2026. During this consulting period, his outstanding equity awards will continue to vest under their current terms, and any unvested awards scheduled to vest during the consulting period will fully vest if a change in control occurs in that timeframe. Vested stock options may be exercised until the earlier of nine months after his consulting ends or their original expiration dates.

Immunovant (IMVT) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $126.5 million for the quarter and $247.1 million for the six-month period, reflecting increased investment in clinical programs. Loss per share was $0.73 for the quarter and $1.43 year-to-date.

Research and development expenses rose to $114.2 million in the quarter (from $97.3 million), driven by potentially registrational trials across endocrine (Graves’ disease), neurology (myasthenia gravis, CIDP), rheumatology (difficult-to-treat RA, Sjögren’s), and a proof-of-concept in dermatology (cutaneous lupus). General and administrative expenses declined to $17.5 million from $18.5 million.

Cash and cash equivalents were $521.9 million, with operating cash outflows of $219.9 million for the six months. Management states this balance is expected to fund announced indications through the Graves’ disease readout in 2027. Shares outstanding were 174,532,710 as of September 30, 2025. The company has an unused at-the-market program of up to $150.0 million and a remaining $39.1 million minimum obligation for batoclimab manufacturing.

Immunovant, Inc. furnished an 8-K announcing a press release with financial results for its fiscal second quarter and six months ended September 30, 2025. The press release is included as Exhibit 99.1.

The company states the information under Item 2.02, including Exhibit 99.1, is furnished, not deemed “filed” under the Exchange Act, and will not be incorporated by reference in other SEC filings. The report was signed by Chief Financial Officer Tiago Girao.

Immunovant (IMVT) insider filing: the Chief Medical Officer reported selling 2,595 shares on October 22, 2025 at a weighted average price of $19.03 (range $19.03–$19.20). The sale was a mandated “sell to cover” to satisfy tax withholding tied to the vesting and settlement of RSUs.

After the transaction, the reporting person beneficially owns 217,958 shares. Footnotes note that 6,250 of a previously granted 100,000 RSUs vested on October 17, 2025.

Immunovant, Inc. (IMVT) disclosed an insider transaction by its Chief Technology Officer, Jay Stout. On 10/22/2025, he sold 2,520 shares of common stock at a weighted average price of $19.03 per share, with trades executed between $19.03–$19.23. The filing states this was a mandated “sell to cover” to satisfy tax withholding arising from the vesting and settlement of 6,250 RSUs on 10/17/2025, part of a 100,000 RSU grant awarded on 04/17/2023, and was not a discretionary transaction.

Following the sale, Stout beneficially owned 200,814 shares, held directly.

Insider sale to cover taxes: The Chief Medical Officer, Michael Geffner, sold 1,272 shares of Immunovant common stock on 10/08/2025 as a sell-to-cover to satisfy tax withholding tied to vested restricted stock units. The weighted average sale price was $16.30 per share (individual trades ranged $16.06–$16.48).

Geffner was granted 54,978 RSUs on 4/2/2024; 3,436 of those RSUs vested on 10/2/2025. After the reported sale, the reporting person beneficially owned 220,553 shares. The filing states the sale was mandated by the issuer's sell-to-cover tax election and not a discretionary transaction.

On 10/08/2025, Chief Technology Officer Jay S. Stout reported the sale of 1,585 shares of Immunovant, Inc. (IMVT) common stock at a weighted average price of $16.3 per share. The shares sold were from the vesting and settlement of restricted stock units granted on 04/02/2024; 3,436 RSUs vested on 10/02/2025. The sale was executed as a mandatory "sell to cover" to satisfy tax withholding and was not a discretionary sale by the reporting person. After the reported transactions, the reporting person beneficially owned 203,334 shares.